US FDA issues CRL to Hikma’s generic version of GSK’s Advair Diskus
pharmaceutical-technology | May 12, 2017
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its.